1260 related articles for article (PubMed ID: 28546454)
1. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Mazidi M; Rezaie P; Gao HK; Kengne AP
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
[TBL] [Abstract][Full Text] [Related]
2. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
Baker WL; Buckley LF; Kelly MS; Bucheit JD; Parod ED; Brown R; Carbone S; Abbate A; Dixon DL
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522675
[TBL] [Abstract][Full Text] [Related]
3. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
5. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
[TBL] [Abstract][Full Text] [Related]
6. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
[TBL] [Abstract][Full Text] [Related]
7. [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Simonyi G
Orv Hetil; 2012 May; 153(18):695-701. PubMed ID: 22547464
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
Liu XY; Zhang N; Chen R; Zhao JG; Yu P
J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
[TBL] [Abstract][Full Text] [Related]
9. The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes.
Shao Y; Lim GJ; Chua CL; Wong YF; Yeoh ECK; Low SKM; Sum CF
Diabetes Res Clin Pract; 2018 Aug; 142():85-91. PubMed ID: 29802956
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitors and renal function.
Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782
[No Abstract] [Full Text] [Related]
11. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Storgaard H; Gluud LL; Bennett C; Grøndahl MF; Christensen MB; Knop FK; Vilsbøll T
PLoS One; 2016; 11(11):e0166125. PubMed ID: 27835680
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
Majewski C; Bakris GL
Diabetes Care; 2015 Mar; 38(3):429-30. PubMed ID: 25715414
[No Abstract] [Full Text] [Related]
13. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
14. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
Liakos A; Karagiannis T; Athanasiadou E; Sarigianni M; Mainou M; Papatheodorou K; Bekiari E; Tsapas A
Diabetes Obes Metab; 2014 Oct; 16(10):984-93. PubMed ID: 24766495
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Zhao D; Liu H; Dong P
J Hum Hypertens; 2019 Apr; 33(4):327-339. PubMed ID: 30443007
[TBL] [Abstract][Full Text] [Related]
17. The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials.
Storgaard H; Gluud LL; Christensen M; Knop FK; Vilsbøll T
BMJ Open; 2014; 4(8):e005378. PubMed ID: 25232561
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Scheen AJ
Clin Pharmacokinet; 2015 Jul; 54(7):691-708. PubMed ID: 25805666
[TBL] [Abstract][Full Text] [Related]
20. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]